Grace Therapeutics, Inc. Common Stock (GRCE)

• Market cap: $28.7M
• 1 day: 2.45%
• 5 days: 5.03%
• 1 month: -8.73%
• 3 months: -42.90%
• 6 months: -36.28%
• Year to date: -47.75%
• 1 year: -34.48%
• 5 years: -93.27%
• 10 years: -99.09%
• Sector: Healthcare
• Industry: Biotechnology

About: Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.

Employees: 4

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

300% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 1

25% more funds holding

Funds holding: 12 [Q3] → 15 (+3) [Q4]

23% more capital invested

Capital invested by funds: $6.36M [Q3] → $7.84M (+$1.47M) [Q4]

0.31% less ownership

Funds ownership: 20.9% [Q3] → 20.59% (-0.31%) [Q4]

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $12 474% upside
• Avg. target: $12 474% upside
• High target: $12 474% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 24 / 50 met price target

474% upside $12

Buy Reiterated

18 Feb 2025